Cerevel Therapeutics Holdings Stock Beta
Cerevel Therapeutics Holdings fundamentals help investors to digest information that contributes to Cerevel Therapeutics' financial success or failures. It also enables traders to predict the movement of Cerevel Stock. The fundamental analysis module provides a way to measure Cerevel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cerevel Therapeutics stock.
Cerevel |
Cerevel Therapeutics Holdings Company Beta Analysis
Cerevel Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Cerevel Therapeutics Beta | 1.41 |
Most of Cerevel Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cerevel Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Cerevel Therapeutics Holdings has a Beta of 1.407. This is 63.6% higher than that of the Biotechnology sector and about the same as Health Care (which currently averages 1.39) industry. The beta for all United States stocks is notably lower than that of the firm.
Cerevel Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cerevel Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics of similar companies.Cerevel Therapeutics is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cerevel Therapeutics will likely underperform.
Cerevel Fundamentals
| Return On Equity | -0.92 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 7.71 B | |||
| Shares Outstanding | 182.2 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 85.12 % | |||
| Number Of Shares Shorted | 5.98 M | |||
| Price To Earning | (0.26) X | |||
| Price To Book | 14.51 X | |||
| EBITDA | (441.64 M) | |||
| Net Income | (432.84 M) | |||
| Cash And Equivalents | 531.21 M | |||
| Cash Per Share | 3.58 X | |||
| Total Debt | 480.78 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 9.52 X | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (342.3 M) | |||
| Short Ratio | 2.37 X | |||
| Earnings Per Share | (2.73) X | |||
| Target Price | 43.4 | |||
| Number Of Employees | 355 | |||
| Beta | 1.41 | |||
| Market Capitalization | 8.19 B | |||
| Total Asset | 1.24 B | |||
| Retained Earnings | (1.4 B) | |||
| Working Capital | 914.76 M | |||
| Current Asset | 9.77 M | |||
| Current Liabilities | 5.22 M | |||
| Net Asset | 1.24 B |
About Cerevel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cerevel Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |